Open AccessPhase 1 Dose-Escalation Study with LEC/Chtnt-3 and Toceranib Phosphate (Palladia) in Dogs with Spontaneous Malignancies
Author(s) -
Julie K. Jang,
John D. Chretin,
David S. Bruyette,
Peisheng Hu,
and Alan L. Epstein
Publication year - 2015
Publication title -
journal of cancer science and therapy
Language(s) - English
Resource type - Journals
ISSN - 1948-5956
DOI - 10.4172/1948-5956.1000343
Subject(s) - medicine , lethargy , neutropenia , gastroenterology , vomiting , cancer , progressive disease , anorexia , tolerability , toxicity , adverse effect , disease
LEC chemokine promotes TH1 responses and recruits immune cells to inflammatory sites. By linking LEC to an antibody targeting tumor necrosis, LEC/chTNT-3 can be used for the immunotherapeutic treatment of tumors. The primary objective of this study was to determine the safety profile of LEC/chTNT-3 and toceranib phosphate (Palladia ® ) combination therapy in dogs with spontaneous malignancies. Secondary purpose was to determine objective responses to treatment.